Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...

Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...

How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View ...

The India State-Level Disease Burden Initiative partners revealed significant variation in age-standardized incidence of the top 10 malignancies, including LC from 1990 to 2016. In men, the crude LC ...

Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. Safety profile of lutetium-177 in patients with impaired renal function: A retrospective ...

Novel urine-enriched RNA panel (EPCAM, TTC3, H4C5) to detect prostate cancer and differentiate it from benign prostatic disease. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Addressing Bias in Feature Importance: A Hybrid Approach for Risk Prediction in Prognostic Survival Models ...

TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

The article by Biller et al entitled “Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome” (JCO Precision Oncology 10.1200/PO-24 ...